The risk of ILD caused by ALK inhibitors is approximately 3%, but we could observe that the risk of developing ILD increased to approximately 10% in a female lung cancer patient who was receiving treatment with brigatinib and concurrently taking amlodipine, as determined by the accumulation of individual risk factors. The gene discussed is ALK; the disease is lung carcinoma.